ziprasidone 20 MG Oral Capsule
1 INDICATIONS AND USAGE Ziprasidone capsules are indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’s greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [see Warnings and Precautions ( 5.3 ) ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see Warnings and Precautions ( 5.3 ) ] Schizophrenia Ziprasidone capsules are indicated for the treatment of schizophrenia in adults [see Clinical Studies ( 14.1 ) ]. Bipolar I Disorder (Acute Mixed or Manic Episodes and Maintenance Treatment as an Adjunct to Lithium or Valproate) Ziprasidone capsules are indicated as monotherapy for the acute treatment of adults with manic or mixed episodes associated with bipolar I disorder [see Clinical Studies ( 14.2 )]. Ziprasidone capsules are indicated as an adjunct to lithium or valproate for the maintenance treatment of bipolar I disorder in adults [see Clinical Studies ( 14.2 ) ]. Ziprasidone capsule is an atypical antipsychotic. In choosing among treatments, prescribers should be aware of the capacity of ziprasidone capsule to prolong the QT interval and may consider the use of other drugs first ( 1 ) Ziprasidone capsules are indicated for the: • treatment of schizophrenia in adults. ( 1 ) • acute treatment of adults as monotherapy of manic or mixed episodes associated with bipolar I disorder. ( 1 ) • maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. ( 1 )
Dr. Reddy's Laboratories Limited
CAPSULE PURPLE RDY 256
Related Pills
ziprasidone 80 MG Oral Capsule
Dr. Reddy's Laboratories Limited
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING Ziprasidone capsules, USP 20 mg (ziprasidone), are light pink to brown granular powder filled in size “4” hard gelatin capsules having Lavender opaque cap and Flesh opaque body, imprinted “RDY” on cap and “256” on body with black ink, and are supplied in bottles of 30’s, 60’s, 90’s, 100’s, 500’s and unit dose package of 30 (3 x 10), unit dose package of 100 (10 x 10). Bottles of 30 NDC 55111-256-30 Bottles of 60 NDC 55111-256-60 Bottles of 90 NDC 55111-256-90 Bottles of 100 NDC 55111-256-01 Bottles of 500 NDC 55111-256-05 Unit-dose packages of 30 (3 x 10) NDC 55111-256-81 Unit-dose packages of 100 (10 x 10) NDC 55111-256-78 Ziprasidone capsules, USP 40 mg (ziprasidone), are light pink to brown granular powder filled in size “4” hard gelatin capsules having Lavender opaque cap and LT turquoise blue opaque body, imprinted “RDY” on cap and “257” on body with black ink, and are supplied in bottles of 30’s, 60’s, 90’s, 100’s, 500’s and unit dose package of 30 (3 x 10), unit dose package of 100 (10 x 10). Bottles of 30 NDC 55111-257-30 Bottles of 60 NDC 55111-257-60 Bottles of 90 NDC 55111-257-90 Bottles of 100 NDC 55111-257-01 Bottles of 500 NDC 55111-257-05 Unit-dose packages of 30 (3 x 10) NDC 55111-257-81 Unit-dose packages of 100 (10 x 10) NDC 55111-257-78 Ziprasidone capsules, USP 60 mg (ziprasidone), are light pink to brown granular powder filled in size “3” hard gelatin capsules having Flesh opaque cap and Flesh opaque body, imprinted “RDY” on cap and “258” on body with black ink, and are supplied in bottles of 30’s, 60’s, 90’s, 100’s, 500’s and unit dose package of 30 (3 x 10), unit dose package of 100 (10 x 10). Bottles of 30 NDC 55111-258-30 Bottles of 60 NDC 55111-258-60 Bottles of 90 NDC 55111-258-90 Bottles of 100 NDC 55111-258-01 Bottles of 500 NDC 55111-258-05 Unit-dose packages of 30 (3 x 10) NDC 55111-258-81 Unit-dose packages of 100 (10 x 10) NDC 55111-258-78 Ziprasidone capsules, USP 80 mg (ziprasidone), are light pink to brown granular powder filled in size “2” hard gelatin capsules having LT turquoise blue opaque cap and Flesh opaque body, imprinted “RDY” on cap and “259” on body with black ink, and are supplied in bottles of 30’s, 60’s, 90’s, 100’s, 500’s and unit dose package of 30 (3 x 10), unit dose package of 100 (10 x 10). Bottles of 30 NDC 55111-259-30 Bottles of 60 NDC 55111-259-60 Bottles of 90 NDC 55111-259-90 Bottles of 100 NDC 55111-259-01 Bottles of 500 NDC 55111-259-05 Unit-dose packages of 30 (3 x 10) NDC 55111-259-81 Unit-dose packages of 100 (10 x 10) NDC 55111-259-78 Ziprasidone capsules, USP should be stored at 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) [See USP Controlled Room Temperature].
More pills like CAPSULE RDY 256